Literature DB >> 9990562

Stability of neurological soft signs in chronically hospitalized schizophrenic patients.

R C Smith1, M I Hussain, S A Chowdhury, A Stearns.   

Abstract

Neurological soft signs (NSS) have been shown to be more prevalent in chronically ill and in acute or never-mediated patients with schizophrenia. If neurological soft signs are trait-like, then NSS scores should be relatively stable over time and should not be related to changes in patients' psychopathology or medication. Chronically hospitalized patients with schizophrenia were rated two or more times over a 5-year period with standard NSS and psychopathology scales. Total NSS scores were highly correlated over time, and changes in NSS scores at two time points were not significantly related to changes in psychopathology scores. Total NSS scores did not change significantly in a subsample rated when they were first treated with a traditional neuroleptic and later with an atypical neuroleptic. The findings suggest total NSS scores may have some characteristics of a trait-like feature in chronically hospitalized patients with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9990562     DOI: 10.1176/jnp.11.1.91

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  11 in total

Review 1.  Very poor outcome schizophrenia: clinical and neuroimaging aspects.

Authors:  Serge A Mitelman; Monte S Buchsbaum
Journal:  Int Rev Psychiatry       Date:  2007-08

Review 2.  [Cortical excitability in schizophrenia. Studies using transcranial magnetic stimulation].

Authors:  T Wobrock; D Kadovic; P Falkai
Journal:  Nervenarzt       Date:  2007-07       Impact factor: 1.214

3.  Neurological soft signs are not "soft" in brain structure and functional networks: evidence from ALE meta-analysis.

Authors:  Qing Zhao; Zhi Li; Jia Huang; Chao Yan; Paola Dazzan; Christos Pantelis; Eric F C Cheung; Simon S Y Lui; Raymond C K Chan
Journal:  Schizophr Bull       Date:  2013-05-13       Impact factor: 9.306

4.  Clinical Utility and Lifespan Profiling of Neurological Soft Signs in Schizophrenia Spectrum Disorders.

Authors:  Raymond C K Chan; Weizhen Xie; Fu-lei Geng; Ya Wang; Simon S Y Lui; Chuan-yue Wang; Xin Yu; Eric F C Cheung; Robert Rosenthal
Journal:  Schizophr Bull       Date:  2015-12-28       Impact factor: 9.306

5.  Patterns of co-altered brain structure and function underlying neurological soft signs in schizophrenia spectrum disorders.

Authors:  Dusan Hirjak; Mahmoud Rashidi; Stefan Fritze; Alina L Bertolino; Lena S Geiger; Zhenxiang Zang; Katharina M Kubera; Mike M Schmitgen; Fabio Sambataro; Vince D Calhoun; Matthias Weisbrod; Heike Tost; Robert C Wolf
Journal:  Hum Brain Mapp       Date:  2019-08-12       Impact factor: 5.038

6.  Can age at sexual maturity act as a predictive biomarker for prodromal negative symptoms?

Authors:  Seethalakshmi Ramanathan; Jean Miewald; Debra Montrose; Matcheri S Keshavan
Journal:  Schizophr Res       Date:  2015-03-14       Impact factor: 4.939

7.  Neurological soft signs in schizophrenia: a meta-analysis.

Authors:  Raymond C K Chan; Ting Xu; R Walter Heinrichs; Yue Yu; Ya Wang
Journal:  Schizophr Bull       Date:  2009-04-17       Impact factor: 9.306

Review 8.  Neurological Soft Signs in Schizophrenia: An Update on the State- versus Trait-Perspective.

Authors:  Silke Bachmann; Johannes Schröder
Journal:  Front Psychiatry       Date:  2018-01-08       Impact factor: 4.157

9.  Neurological Soft Signs and Psychopathology in Chronic Schizophrenia: A Cross-Sectional Study in Three Age Groups.

Authors:  Christina J Herold; Marc M Lässer; Ulrich Wilhelm Seidl; Dusan Hirjak; Philipp A Thomann; Johannes Schröder
Journal:  Front Psychiatry       Date:  2018-03-26       Impact factor: 4.157

10.  Neurological Signs at the First Psychotic Episode as Correlates of Long-Term Outcome: Results From the AESOP-10 Study.

Authors:  Naika P Ferruccio; Sarah Tosato; Julia M Lappin; Margaret Heslin; Kim Donoghue; Annalisa Giordano; Ben Lomas; Ulrich Reininghaus; Adanna Onyejiaka; Raymond C K Chan; Tim Croudace; Peter B Jones; Robin M Murray; Paul Fearon; Gillian A Doody; Craig Morgan; Paola Dazzan
Journal:  Schizophr Bull       Date:  2021-01-23       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.